Advertisement

The Effect of Beta Glucan on Cisplatin Ototoxicity

  • Tuba Bayindir
  • Mustafa Iraz
  • Mehmet Kelles
  • Serdar Kaya
  • Mehmet Tan
  • Aliye Filiz
  • Yuksel Toplu
  • M. Tayyar KalciogluEmail author
Original Article

Abstract

This study was undertaken to investigate the effect of betaglucan in ameliorating cisplatin ototoxicity. Rats were divided into four groups: cisplatin (C), cisplatin plus beta glucan (CB), beta glucan (B), and control (K). Distortion product otoacoustic emissions were elicited in 0th, 1st, and 5th days. For the group C differences were observed at 8,003 and 9,515 Hz between 0th and 5th days’ measurements. In the group CB there were differences at frequencies of 3,996, 4,757, 5,660, and 6,726 Hz between 0th and 5th days’ measurements. For the group B there were significant recovery in some frequencies. The observation of significant deterioration in terms of hearing in the group treated with cisplatin plus betaglucan may be suggested that depended on the increase of permeability and tissue conductance into the inner ear which may be caused by betaglucan. Further long-term follow-up studies by using different doses may clarify this matter.

Keywords

Ototoxicity Cisplatin Betaglucan Otoacoustic emissions 

Notes

Acknowledgments

The authors would like to thank Professor Saim Yologlu, M.S., M.D., from the Inonu University Medical Faculty’s Department of Biostatistics, for contributing to the statistical evaluation.

References

  1. 1.
    Tsang RY, Al-Fayea T, Au HJ (2009) Cisplatin overdose: toxicities and management. Drug Saf 32:1109–1122PubMedCrossRefGoogle Scholar
  2. 2.
    Blakley BW, Gupta AK, Myers SF, Schwan S (1994) Risk factor for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120:541–546PubMedCrossRefGoogle Scholar
  3. 3.
    de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ et al (2003) Weekly high-dose cisplatin in a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199–1206. doi: 10.1038/sj.bjc.6600884 PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Cleary JA, Kelly GE, Husband AJ (1999) The effect of molecular weight and β-1,6-linkages on priming of macrophage function in mice by (1,3)- β-D-glucan. Immunol Cell Biol 77:395–403PubMedCrossRefGoogle Scholar
  5. 5.
    Jordan J, Schwade ND, Truelson JM (1999) Fosfomycin does not inhibit the tumoricial efficacy of cisplatinum. Laryngoscope 109:1259–1262. doi: 10.1097/00005537-199908000-00014 PubMedCrossRefGoogle Scholar
  6. 6.
    Feghali JG, Liu W, Water TRVD (2001) L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111:1147–1155. doi: 10.1097/00005537-200107000-00005 CrossRefGoogle Scholar
  7. 7.
    Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66:19–23PubMedGoogle Scholar
  8. 8.
    Tampakopoulou DA, Sie KC (1999) Cisplatin ototoxicity in developing gerbils. Hear Res 132:51–59. doi: 10.1016/S0378-5955(99)00033-7 PubMedCrossRefGoogle Scholar
  9. 9.
    Fausti SA, Frey RH, Henry JA, Olson DJ, Schaffer HI (1993) High-frequency testing techniques and instrumentation for early detection of ototoxicity. J Rehabil Res Dev 30:333–341PubMedGoogle Scholar
  10. 10.
    Ravi R, Somani SM, Rybak LP (1995) Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76:386–394PubMedCrossRefGoogle Scholar
  11. 11.
    Rybak LP, Whitworth CA, Mukherjea D, Ramkuvar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157–167. doi: 10.1016/j.heares.2006.09.015 PubMedCrossRefGoogle Scholar
  12. 12.
    Young SG, Parthasarathy S (1994) Why are low-density lipoproteins atherojenic? West J Med 160:153–164PubMedCentralPubMedGoogle Scholar
  13. 13.
    Ichikiawa I, Kiyama S, Yoshioka T (1994) Renal antioxidant enzymes: their regulation and function. Kidney Int 45:1–9. doi: 10.1038/ki.1994.1 CrossRefGoogle Scholar
  14. 14.
    Kalcioglu MT, Kizilay A, Gulec M, Karatas E, Iraz M, Akyol O, Egri M, Ozturan O (2005) The protective effect of erdosteine against ototoxicity by cisplatin in rats. Eur Arch Otorhinolaryngol 262:856–863. doi: 10.1007/s00405-004-0909-7 PubMedCrossRefGoogle Scholar
  15. 15.
    Kizilay A, Kalcioglu MT, Ozerol E, Iraz M, Gulec M, Akyol O, Ozturan O (2004) Caffeic acid phenethyl ester ameliorated ototoxicity ınduced by cisplatin in rats. J Chemother 16:381–387PubMedCrossRefGoogle Scholar
  16. 16.
    Iraz M, Kalcioglu MT, Kizilay A, Karatas E (2005) Aminoguanidine prevent ototoxicity induced by cisplatin in rats. Ann Clin Lab Sci 35:329–335PubMedGoogle Scholar
  17. 17.
    Karaduman D, Eren B, Keles ON (2010) The protective effect of beta-1,3-D-glucan on taxol-induced hepatotoxicity: a histopathological and serological study. Drug Chem Toxicol 33:8–16. doi: 10.3109/01480540903380472 PubMedCrossRefGoogle Scholar
  18. 18.
    Ewaschuk JB, Johnson IR, Madsen KL, Vasanthan T, Ball R, Field CJ (2012) Barley-derived beta-glucans increases gut permeability, ex vivo epithelial cell binding to E. coli, and naive T-cell proportions in weanling pigs. J Anim Sci 90:2652–2662. doi: 10.2527/jas2011-4381 PubMedCrossRefGoogle Scholar
  19. 19.
    Bayindir T, Filiz A, Iraz M, Kaya S, Tan M, Kalcioglu MT Evaluation of protective effect of beta glucan on amikacin ototoxicity using distortion product otoacoustic emission measurements in rats. Clin Exp Otorhinolaryngol (in press)Google Scholar

Copyright information

© Association of Otolaryngologists of India 2013

Authors and Affiliations

  • Tuba Bayindir
    • 1
  • Mustafa Iraz
    • 2
  • Mehmet Kelles
    • 3
  • Serdar Kaya
    • 1
  • Mehmet Tan
    • 1
  • Aliye Filiz
    • 1
  • Yuksel Toplu
    • 1
  • M. Tayyar Kalcioglu
    • 4
    Email author
  1. 1.Department of OtorhinolaryngologyMedical Faculty, Inonu UniversityMalatyaTurkey
  2. 2.Department of PharmacologyIstanbul Medeniyet UniversityIstanbulTurkey
  3. 3.Department of OtorhinolaryngologySutcu Imam UniversityKahramanmarasTurkey
  4. 4.Department of OtorhinolaryngologyMedical Faculty, Istanbul Medeniyet University, Goztepe HospitalIstanbulTurkey

Personalised recommendations